Sulfamethoxazole/Trimethoprim

磺胺甲噁唑/甲氧苄啶

Report date: 2026/05/28 20:00:21

Base Information

Drug NameSulfamethoxazole/Trimethoprim
Drug Alias NameCo-trimoxazole甲氧苄啶磺胺甲噁唑Trimethoprim/Sulfamethoxazole磺胺甲噁唑甲氧苄啶Sulfamethoxazole and Trimethoprim +[12] 
ClassificationSmall molecules
Mechanisms of ActionDihydropteroate synthase inhibitors
TargetsDihydropteroate synthaseDihydrofolate reductase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Drug-Related Side Effects and Adverse ReactionsDiarrhea +[32] 
Global Approved IndicationsDiarrheaOtitis MediaEnteritis +[9] 
Approved Indications in ChinaBacterial Infections
Original Approved Country/TerritoryUnited States
Original Approved Date1973/07/30
Country/TerritoryCanadaUnited StatesNetherlands +[10] 
CombinationsYes TrimethoprimSulfamethoxazole
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesPfizer Inc
China Registration ClassN/A

Develop Information

Active CompaniesHospital Civil De GuadalajaraUniversity College LondonResearch Institute Of The Mcgill University Health Centre +[10] 
Inactive CompaniesUniversity Medical Center GroningenMonarch Pharmaceuticals LlcJohns Hopkins University +[8] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)DiarrheaAcute Kidney Injury +[16] 
Inactive IndicationsDrug-Related Side Effects and Adverse ReactionsPostoperative ComplicationsVesico-Ureteral Reflux +[16] 

Other Information

ATC CodeJ01EE01
Related LinksWikipediaKEGG